Lactobacillus reuteri.

Inulin is a fructan that human enzymes cannot break down but lactobacilli ferment to lactate and short-chain fatty acids, lowering colonic pH. Pairing a strain with its substrate is the original synbiotic design.

Partially hydrolysed guar gum ferments steadily along the colon and supports lactic acid bacteria without the viscosity of intact guar. It is a common carrier fibre in strain formulations.

Pectin is fermented by resident lactic acid bacteria into short-chain fatty acids, and its gel also slows transit so organisms spend longer in contact with substrate.

Oat beta-glucan reaches the colon intact and is fermented by lactic acid bacteria, adding substrate for lactate production. The fibre also raises viscosity in the upper gut, which affects transit speed.

Lactobacilli produce lactate, which butyrate-forming bacteria take up and convert onward, so lactate output and butyrate supply are linked in one cross-feeding chain. Supplying butyrate covers the downstream end of that chain.

Glutamine is the main respiratory substrate for small intestinal cells and supports normal tight-junction protein expression, working on the host side of the barrier while the strain works on the luminal side.

Colostrum carries secretory immunoglobulins and milk oligosaccharides, and those oligosaccharides are substrate that lactobacilli ferment. It is a long-standing pairing in gut formulations.

Lactic acid bacteria carry their own beta-galactosidase, so they break down some lactose in the gut alongside a supplemental lactase enzyme. The two act on the same substrate by different routes.

Lactobacillus reuteri is one of the few lactic acid bacteria carrying cobalamin biosynthesis genes and making corrinoid compounds. That places the strain and the vitamin on the same cobamide pathway, though microbial output is not a substitute for dietary intake.

Carvacrol and thymol disrupt bacterial membranes without distinguishing lactic acid bacteria from other organisms, so taking them at the same time lowers delivered viable counts. Formulators separate the doses rather than blend them.

Berberine has direct antibacterial activity in the gut lumen and shifts community composition, which works against a live-organism dose given at the same time. Staggering the two is the standard handling.

Activated charcoal adsorbs organic molecules broadly in the gut lumen, including the nutrients and substrates a delivered strain needs. Anything taken with charcoal should be spaced by a couple of hours.

Galactooligosaccharides pass to the colon undigested and are fermented by lactobacilli and bifidobacteria. Supplying a substrate alongside the organism is the standard synbiotic construction. Whether it increases what the delivered strain actually does in a given person is not settled.

Short-chain fructans are fermented by resident lactobacilli to lactate and acetate, lowering local pH. Pairing them with a delivered strain adds substrate at the site the strain has to compete in. The commonest practical issue is gas during the first week.

Resistant starch reaches the colon intact and is fermented largely to butyrate by cross-feeding communities. L. reuteri is a lactate and acetate producer, and those acids are substrate for the butyrate producers downstream. The pairing works through cross-feeding rather than through a direct effect on the strain.

Chicory-derived inulin is a longer-chain fructan fermented more slowly and further along the colon than short-chain fructans. That spreads fermentation over a larger stretch of bowel. It is a substrate contribution, not a change in what the strain itself does.

Pectin is fermented by a broad set of colonic organisms and contributes to short-chain fatty acid production. It is a gentler substrate than fructans for people who react to those. No combination trial with this species is available.

S. boulardii is a yeast and is unaffected by antibacterial pressure that would reduce a delivered bacterial strain. The two occupy different niches and are commonly combined for that reason. The pairing is formulation logic supported by each organism's own literature, not by a head-to-head combination trial.

L. plantarum is facultatively heterofermentative and L. reuteri is obligately heterofermentative, so they handle sugars differently and produce different acid mixes. Multi-strain products combine them for that breadth. Multi-strain formulas are also harder to attribute an effect to, since strain-specific results do not transfer across a blend.

Bifidobacteria dominate the infant colon and lactobacilli the small intestine, so the two genera address different sites. Products pair them to cover both. Evidence for the combination is weaker than for either genus studied alone.

B. lactis tolerates oxygen and processing better than most bifidobacteria, which is why it appears in shelf-stable blends alongside L. reuteri. The pairing is a stability and coverage decision. It is not evidence that the two act together.

Lactoferrin sequesters free iron, which restrains iron-requiring organisms, and lactobacilli have low iron requirements compared with many gut bacteria. That difference is the stated basis for pairing the two. It is mechanistic reasoning drawn from each ingredient's own literature.

Zinc supports the expression of tight junction proteins that hold the intestinal barrier together, and probiotic organisms are studied for effects on the same barrier. The two reach the endpoint by different routes. Combination products exist, but the pairing itself has not been isolated in a trial here.

Vitamin D receptor signalling in the gut epithelium influences barrier proteins and antimicrobial peptide expression. That is a separate route to the same tissue a delivered strain interacts with. Any combined benefit is inference from two separate literatures, not a measured combination.

Gastric acid is the main barrier to delivering viable organisms to the intestine. Raising gastric pH, whether by a buffering agent or by taking the dose with food, increases the fraction that survives transit. This is a delivery effect, not a change in what the organism does once it arrives.

Catechins inhibit a range of bacteria in culture, and some lactobacilli in turn metabolise them into smaller phenolic acids. The relationship runs both ways and has been characterised mostly in test systems. Nothing here supports a claim in either direction for a person.